Skip to main content
NewslettersWatchlist

Sage Therapeutic Com(SAGE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low10.60
Day High11.00
Open:10.94
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
The Globe and Mail
Market movers: Stocks seeing action on Tuesday - and why
Barchart
Stocks Close Lower as Bond Yields Climb
Barchart
Stocks Slide on Higher Bond Yields
Barchart
Stocks Tumble on Concern Interest Rates Will Stay Higher for Longer
GlobeNewswire
ZURZUVAEโ„ข (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
Motley Fool
Why Sage Therapeutics Stock Sank Today
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
Motley Fool
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
PR Newswire
SAGE INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
Motley Fool
Why Shares of Sage Therapeutics Slumped This Week
Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
Motley Fool
Is Sage Therapeutics a Contrarian Buy?
Motley Fool
Why Sage Therapeutics Stock Is Crashing Today
GlobeNewswire
FDA Approves ZURZUVAEโ„ขย (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Motley Fool
Why Sage Therapeutics Stock Is Tumbling Today
Business Wire
Sage Therapeutics to Present at Upcoming May Investor Conferences
Business Wire
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
Business Wire
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
Business Wire
Sage Therapeutics to Present at the Stifel 2023 CNS Days
ACCESSWIRE
Sage Potash Announces Exchange Listing

Profile

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.